• Japan Lifeline maintained its full-year outlook at its October 30, 2026, second-quarter results briefing for the fiscal year ending March 2027.
• Attendees included Keisuke Suzuki, Tatsuya Murase, Takeyoshi Egawa, Takashi Ito and investor relations representative Fumiya Shinohara.
• First-half revenue rose 7.1% to JPY 31.35 billion, supported by EP/Ablation and Neurovascular sales.
• Operating profit fell 17.4% to JPY 5.47 billion as increased research spending, personnel costs and acquisition-related fees weighed.
• Management targets approximately JPY 10 billion in US sales around 2032, using acquired Cross Vascular to accelerate market entry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JLL - Japan Lifeline Co. Ltd. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.